Axxam S.p.A. and Momentum Biotechnologies have recently formed a partnership to deliver innovative drug discovery solutions for clients in the biotechnology and pharmaceutical industries. The collaboration involves making Axxam's chemical diversity library, consisting of 325,000 compounds, available for high-throughput screening through Momentum's mass spectrometry-based functional and binding assay platforms. Identified primary hits can be further developed in hit-to-lead projects, along with additional downstream experiments, including testing in cell-based assays.

Axxam is a leading provider of early drug discovery services, offering not only its extensive chemical diversity library but also a broad range of applications. The library is the result of decades of screening experience and significant input from medicinal and computational chemists, featuring small molecules selected for both quality and structural diversity.

Momentum Biotechnologies, a bioanalytical contract research organization (CRO), specializes in early drug discovery and provides high-throughput functional and binding assays based on mass spectrometry. Founded by the team behind the commercialization of the RapidFire™ high-throughput mass spectrometry platform, the company brings decades of experience in screening and hit characterization to the collaboration.

Momentum, expressed enthusiasm about the collaboration, stating, "We are thrilled to enter this collaboration with Axxam. Our clients will now have the option to access additional chemical matter for their drug discovery programs, further enhancing our affinity selection mass spectrometry and functional assay services."

Axxam, added, "With this collaboration, Axxam clients will now have access to mass spectrometry-based HTS and hit-to-lead technologies, expanding upon the wide range of services existing within the Axxam portfolio."

 

Source: prnewswire.com

Report Abuse